News & Events
Keyword Search
 
2017 | 2016
DateTitle 
03/15/17David Moatazedi Joins Obalon Therapeutics, Inc. Board of Directors
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) --  Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that David Moatazedi, Senior Vice President, US Medical Aesthetics for Allergan plc has been appointed to its board of directors.  Mr. Moatazedi is the second addition to the Obalon board of directors in 2017, as Obalon continues its launch of the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intragastric bal... 
02/23/17Obalon Therapeutics, Inc. Announces Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2016. “2016 was a transformative year for Obalon. We submitted our PMA filing for approval of the Obalon balloon system in January 2016 and recei... 
02/15/17Obalon Therapeutics Inc Announces Fourth Quarter and Year End 2016 Financial Results Conference Call
SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the fourth quarter and full year ending December 31, 2016, before the market opens on Thursday, February 23, 2017. The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern ... 
01/19/17Obalon Therapeutics, Inc. to Ring The Nasdaq Stock Market Closing Bell
SAN DIEGO, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that they will be ringing the Nasdaq Stock Market closing bell, to recognize the recent launch of the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss.  Physicians began treating patients with the Obalon Balloon System last week. “On September 8th, Obalon received approval f... 
01/17/17Jonah Shacknai Joins Obalon Therapeutics, Inc. Board of Directors
Mr. Shacknai Joins Raymond Dittamore and Les Howe As Newest Additions to Board SAN DIEGO, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that Jonah Shacknai, Executive Chairman of DermaForce and former Chairman and Chief Executive Officer of Medicis has been elected to its board of directors.  Mr. Shacknai joins Raymond Dittamore and Les Howe as the latest members of Obalon Therapeutic’s board of di... 
01/13/17Obalon Announces Initial Commercial Patient Placements of the First and Only Swallowable, FDA-Approved Balloon System for Weight Loss
SAN DIEGO, Calif., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced that it has begun U.S. commercial shipments of the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intragastric balloon system for weight loss. The first patients have been treated by physicians in key metropolitan markets across the United States. Candidates for Obalon are adults 30 to 100 pounds overweight an... 
Upcoming Events
There are currently no events scheduled.
Past Events
DateTitle
02/23/17 8:30 a.m. ET
Obalon Fourth Quarter 2016 Conference Call
11/11/16 5:00 a.m. PT
Obalon Third Quarter 2016 Conference Call
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling